Altachem shareholders approve resolutions at the company's September 15, 2005 annual general meeting

- Company to adopt new name, "Quest PharmaTech Inc" -

Trading Symbol: AAF: TSX Venture Exchange

EDMONTON, Sept. 19 /CNW/ - At the Company's annual general meeting held
August 15, 2005 the following resolutions were approved by the Company's
shareholders:

1.  - Election of the Board of Directors for the coming year
    a.  Dr. Ragupathy ("Madi") Madiyalakan, Chairman
    b.  Dr. David Cox, President and CEO
    c.  Dr. Selvaraj Naicker, Interim Chief Operating Officer
    d.  Mr. Ian McConnan, Partner, Harris McConnan
    e.  Dr. Don Rix, Chairman, MDS Metro Laboratory Services
    f.  Mr. Richard H. ("Rick") Smith, President and CEO, Dow
        AgroSciences Canada Inc.
2.  Changing the name of the Company from Altachem Pharma Ltd to Quest
    PharmaTech Inc.
3.  Re-appointment of Ernst & Young LLP, Chartered Accountants, as the
    auditors of the Company for the coming year and to authorize the
    board to fix the remuneration to be paid to the auditors
4.  Approval of the amended stock option plan to change the maximum
    numbers of common shares that may be reserved for issuance under the
    plan from a fixed number to a 10 percent rolling plan.
5.  Repeal of the existing By-Laws and adoption of new By-Laws

"The approval of these resolutions is a reflection of our shareholders'
support for management and the board of the Company" commented Dr. David Cox,
President and CEO. "These steps will allow the company to continue to move
forward with its plans for future drug development. I am particularly excited
about the adoption of a new name and branding for the Company which is
intended to underscore the strategic repositioning announced earlier this
year"
The Company is seeking TSX(V) approval for a new stock symbol.

About Altachem Pharma Ltd

The Corporation is a publicly traded (TSX Venture Exchange: AAF),  
Alberta-based pharmaceutical company committed to the development and
commercialization of new pharmaceutical products. It is developing a series of
products for the treatment of cancer and other proliferative diseases based on
its SonoLight and CDK platforms. It also has a profitable product in       
Accu-MAb(TM), a monoclonal-based diagnostic kit for whooping cough.
Except for historical information, this press release may contain  
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."
%SEDAR: 00008400E